Acquisition expands Corza's portfolio of ophthalmic surgery products
CHICAGO and WESTWOOD, Mass. , June 8, 2022 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that its portfolio company Corza Medical ("Corza"), a leading global manufacturer of innovative surgical technologies, has acquired Barron Precision Instruments, LLC ("BPI"), a founder-owned medical device company focused on ophthalmic surgery products.
Founded in 1948 and headquartered in Grand Blanc, Michigan , BPI has over 70 years of experience manufacturing disposable medical devices. BPI is a leader in ophthalmic products used in corneal surgeries, delivering unique designs and innovative technologies to patients suffering from corneal disease across the globe.
The acquisition of BPI enhances Corza's portfolio of surgical products and expands the company's manufacturing footprint. This transaction represents Corza's second add-on acquisition since its formation in January 2021 and follows the transformative acquisition of Katena Products, Inc. in December 2021 , which served as the foundation of its Corza Ophthalmology business unit.
"The addition of BPI is highly complementary to our existing ophthalmic surgery portfolio," said Greg Lucier , Executive Chairman of Corza. "The acquisition of BPI broadens our ability to target various disease states and highlights our dedication to building Corza through M&A. We look forward to continuing to support the customer base with an unwavering commitment to product quality and customer service."
"For more than seven decades, BPI and the Barron family have delivered trusted performance and consistent innovation serving the corneal transplant market," said Dan Croteau , CEO of Corza. "The acquisition of BPI reinforces Corza's commitment to providing exceptional service and value to our customers, transforming surgical outcomes and changing the lives of patients. We look forward to having the highly skilled team at BPI join the global Corza family."
Sean Cunningham , Managing Director and Co-Head of Healthcare at GTCR, added: "The Barron family and the BPI team have built a resilient business with excellent products that are highly valued by customers. The acquisition of BPI accelerates Corza's momentum and expands its attractive portfolio of growing products in ophthalmics, wound closure and biosurgery. We are excited to continue supporting Corza's growth initiatives, investing in its strategic platforms and building out its portfolio with continued M&A."
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications industries. The Chicago -based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $20 billion in over 250 companies. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
Corza Medical is a leading global manufacturer of innovative surgical technologies. With a global team of over 1,800 employees supporting clinicians, distributors and medical device companies worldwide, Corza provides healthcare professionals a platform of surgical technologies with industry-leading brands, including Quill™ barbed sutures, Sharpoint™ Plus and Look™ surgical sutures, Katena™ and Blink Medical ophthalmic instruments, and the TachoSil® fibrin sealant patch. For more information, please visit www.corza.com.
Headquartered in Grand Blanc, Michigan , Barron Precision Instruments, LLC (BPI) is a privately owned company that has over 70 years of experience in the fabrication of sterile, disposable medical devices. The Company currently focuses primarily on manufacturing quality instruments for use in the surgical treatment of the human eye. For more information, please visit www.bpic.com.
CONTACT: Kellie Kennedy , kelliek@theharbingergroup.com, 312-933-4903
View original content to download multimedia:https://www.prnewswire.com/news-releases/gtcr-and-corza-announce-acquisition-of-barron-precision-instruments-301563621.html
Bill Gates looks for income, too. This is how he gets it.
‘Rich Dad Poor Dad’ sees a window to get rich. He might be right.
Feeling bearish? Take shelter — and income.
Among six high-profile stock splits -- Alphabet, Amazon, Tesla, Shopify, DexCom, and Palo Alto Networks -- is a clear-cut bargain, as well as a company with serious red flags.
There's a lot of pride associated with owning property, whether it's a primary home or a vacation bungalow. It's especially rewarding when real estate is properly compensated for. But while a high selling price may be exciting in the moment, … Continue reading → The post How to Avoid Capital Gains Tax When Selling a House appeared first on SmartAsset Blog.
The housing market is changing fast. Act accordingly.
Nio (NYSE: NIO) is a leading player in China's electric vehicle (EV) market and has sometimes been referred to as the "Chinese Tesla." Should investors treat Nio's big valuation pullback as an opportunity to build a position in the stock, or is the EV company's share price still too high to generate strong returns? Howard Smith: Nio's recently released quarterly earnings report provided a good lesson for investors wanting to log big returns on more speculative, high-growth companies.
Tough times ahead. But you don't need to sell it all.
There's a bond that pays a 9.62% interest rate and is guaranteed by the U.S. Treasury. Investors should keep some limitations and conditions in mind before investing, but as inflation has topped 8% since March 2022, this could be an … Continue reading → The post Want 9.62% Yield Guaranteed? Seriously, Try This Asset appeared first on SmartAsset Blog.
The Nasdaq Composite index's level is down roughly 25% year to date, and many semiconductor stocks have seen huge sell-offs across 2022's trading. In addition to concerns about the possibility of a prolonged recession and other macroeconomic pressure affecting the broader market, manufacturing issues and geopolitical risk factors have also caused investors to move out of semiconductor stocks. Nvidia (NASDAQ: INTC) and Intel (NASDAQ: NVDA) are leading chip companies that have seen big sell-offs, and their stocks now trade down roughly 40% and 53% this year, respectively.
Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett is one of the best investors of our lifetime. Buffett stands out, in part, because he doesn't tend to follow the crowd, doesn't fear market crashes, and has a knack for putting his cash to work when everyone else is fearful. Buffett has explained that he looks to buy quality companies with management teams he likes and that he buys with the intention of holding on to these investments for years or even decades.
The biotech sector, like most sections of the market, took a sound beating in the year’s first half. Recently, however, the segment’s performance has improved, and that has helped the NASDAQ Biotechnology Index (NBI) pull ahead of the NASDAQ (Up 13% over the past 3 months vs. the NASDAQ’s 3%). The Oppenheimer biotech team thinks there’s a simple explanation for this: “We believe that much of the recent outperformance has been driven by SMID caps, of which many have risen admirably in the past fe
This past week, average 30-year mortgage rates crossed the 6% mark — though many borrowers can still snag lower lower rates than that — after staying below that for most of July and August, Bankrate data revealed. Greg McBride, chief financial analyst at Bankrate, says the economy will slow faster than inflation so more yo-yo action with rates should be expected in September, but it won’t be huge swings we’re seeing. According to the National Association of Realtors, (NAR), data is showing that mortgage rates have already priced in the upcoming Fed rate hikes.
As home prices soared in recent years, homeowners enjoyed record levels of tappable home equity, which is the amount of money a homeowner can borrow against while keeping a 20% equity stake. One big reason why tappable equity is down is, of course, that home prices are down.
The Biden administration plans next month to broaden curbs on U.S shipments to China of semiconductors used for artificial intelligence and chipmaking tools, several people familiar with the matter said. The Commerce Department intends to publish new regulations based on restrictions communicated in letters earlier this year to three U.S. companies -- KLA Corp, Lam Research Corp and Applied Materials Inc, the people said, speaking on the condition of anonymity. The letters, which the companies publicly acknowledged, forbade them from exporting chipmaking equipment to Chinese factories that produce advanced semiconductors with sub-14 nanometer processes unless the sellers obtain Commerce Department licenses.
In today's volatile market, there's a lot to be said for seeking out boring businesses at cheap prices.
As different as they seem, both quiet-quitters and FIRERS want the same thing.
Developing innovative products is an excellent way for a company to become successful, and that's what Inovio Pharmaceuticals (NASDAQ: INO) is looking to do. Let's look at one reason Inovio could be an exciting contrarian buy, and one reason to stay away. Small-cap biotechs need promising pipeline programs to attract attention.
Former President Donald Trump has been hinting here and there about who his potential running mate would be for the 2024 presidential run, not confirming or denying anything surrounding that notion. That is, until now. In a recent interview with India’s NDTV, Trump was asked if his eldest daughter Ivanka Trump would be his running […]
If you want to secure a decent yield, it can pay to buy shares of strong companies dealing with short-term problems.